1. Medtech Insight
  2. >>Policy & Regulation
  3. >>Legal & IP

Patent Board Rejects Edwards’ Heart Valve Claim-Review Request

 
• By Elizabeth Orr

The US Patent Office has rejected a request by Edwards Lifesciences to review an Abbott patent on heart-valve technology, which could establish the patent as a key part of Abbott Laboratories’ arguments in a larger ongoing intellectual property case.

MT1911_Patent Law_746396146_1200.jpg

The US Patent and Trademark Office’s rejection of a request from Edwards LifeSciences to review a heart-valve technology patent may be a good sign for Abbott Laboratories in ongoing patent litigation between the two companies, analysts say.

Edwards had asked the Patent and Trademark Office (PTO) for inter partes review of a patent on cardiac valve-repair technology that is held by Evalve Inc. but licensed to Abbott. The patent is one of five involved in pending litigation between Abbott and Edwards over whether Edwards’ Pascal transcatheter valve-repair system violates patents supporting Abbott’s MitraClip. Edwards says Pascal doesn’t infringe any valid patents

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Legal & IP

More from Policy & Regulation

‘Help Us Deregulate’: RFK Announces RFI For Trimming Government Health Agencies

 
• By Brian Bossetta

HHS Secretary Robert F. Kennedy, Jr. is asking the public to help cut waste across the government’s health agencies. Kennedy announced a 60-day comment period allowing the public to take part in a broader federal initiative to reduce regulations and increase transparency.

MedTech Europe’s Bisazza Urges Action As US Tariffs Jeopardize Critical Global Supply Chains

 
• By Amanda Maxwell

The intricate assembly of medical devices, often involving over 1,000 globally sourced components, faces severe disruption due to new US tariffs. These barriers could halt production and devastate small and medium-sized enterprises (SMEs), MedTech Europe’s CEO, Oliver Bisazza, warns in an interview with Medtech Insight.

UK Medtech Regulators Must Ensure Certainty So Businesses Can Plan Their Futures

 
• By Ashley Yeo

With medtech businesses typically managing investment cycles on a three- to five-year basis, local regulatory processes and forward costs of market entry must offer an attractive environment in which companies can plan for growth, says McDermott Will and Emery’s partner and head of healthcare and life sciences, Sharon Lamb. Broad-scale improvements to NICE’s evaluation offerings would similarly enhance the UK’s value to innovators.